Passage Bio Soars 12.39% on Institutional Buying Spree

On July 25, 2025, Passage Bio's stock surged by 12.39% in pre-market trading, reflecting significant investor interest and potential market momentum.

Lynx1 Capital Management LP, a major shareholder, has been actively acquiring Passage Bio shares. The firm purchased 13,123 shares on July 22, 2025, followed by 49,302 shares on July 23, 2025, and 66,423 shares on July 24, 2025. These transactions indicate a strong bullish sentiment from institutional investors, which could be driving the recent price increase.

OrbiMed, another significant investor, has reduced its stake in Passage Bio to 4.25% by selling 104,049 shares post-split. This move suggests a shift in the shareholder mix and could influence market dynamics, as major investors adjust their positions.